Cardiac Pathology in Status Epilepticus
Ann Neurol 58:954-957, Manno,E.M.,et al, 2005
Global Prevalence of Dementia: A Delphi Consensus Study
Lancet 366:2112-2117, Ferri,C.P.,et al, 2005
Treatment Delay and the Risk of Prolonged Status Epilepticus
Neurol 65:1316-1318, Eriksson,K.,et al, 2005
Risk of Death With Atypical Antipsychotic Drug Treatment for Dementia, Meta-analysis of Randomized Placebo-Controlled Trials
JAMA 294:1934-1943,1963, Schneider,L.S.,et al, 2005
Delayed Neurotoxicity in Primary Central Nervous System Lymphoma
Arch Neurol 62:1595-1600, Omuro,A.M.P.,et al, 2005
Status Epilepticus: An Evidence Based Guide
BMJ 331:673-677, Walker,M., 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005
Occupation and Parkinsonism in Three Movement Disorders Clinics
Neurol 65:1430-1435, Goldman,S.M.,et al, 2005
Excessive Daytime Sleepiness and Subsequent Development of Parkinson Disease
Neurol 65:1442-1446, Abbott,R.D.,et al, 2005
Levodopa Addiction in Idiopathic Parkinson Disease
Neurol 65:1508, Borek,L.L &Friedman,J.H., 2005
Lipid Lowering Agents Are Associated With a Slower Cognitive Decline in Alzheimers Disease
JNNP 76:1624-1629, Masse,I.,et al, 2005
Modafinil for Daytime Somnolence in Parkinsons Disease: Double Blind, Placebo Controlled Parallel Trial
JNNP 76:1636-1639, Ondo,W.G.,et al, 2005
The Role of Levodopa in the Management of Dementia With Lewy Bodies
JNNP 76:1200-1203, Moloy,S.,et al, 2005
Cholinesterase Inhibitors for Patients with Alzheimers Disease: Systematic Review of Randomised Clinical Trials
BMJ 331:321-323, Kaduszkiewicz,H.,et al, 2005
Propofol and Thiopental for Refractory Status Epilepticus in Children
Neurol 65:591-592,506, van Gestel,J.P.J.,et al, 2005
Carbamazepine Encephalopathy Masquerading as Creutzfeldt-Jakob Disease
Neurol 65:650-651, Horvath,J.,et al, 2005
Clinicopath Conf, Prion Disease (Sporadic Creutzfeldt-Jakob Disease)
NEJM 353:1042-1050, Case 27-2005, 2005
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Science and Ethics of Sham Surgery, A Survey of Parkinson Disease Clinical Researchers
Arch Neurol 62:1357-1360,1343, Kim,S.Y.H.,et al, 2005
Neurologic Spectrum of Chronic Liver Failure and Basal Ganglia T1 Hyperintensity on Magnetic Resonance Imaging, Probably Manganese Neurotoxicity
Arch Neurol 62:1385-1390, Klos,K.J.,et al, 2005
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
The "Electrocuted" Hippocampus
Lancet 366:956-957, Uncini,A.,et al, 2005
The "Pulvinar Sign" in a Case of Paraneoplastic Limbic Encephalitis Associated with Non-Hodgkins Lymphoma
JNNP 76:882-884, Mihara,M.,et al, 2005
Ictal Cardiorespiratory Arrest in Panayiotopoulos Syndrome
Neurol 64:1816-1817, Verrotti,A.,et al, 2005
Short-Term Paroxetine Treatment Does Not Alter the Motor Response to Levodopa in PD
Neurol 64:1797-1798, Chung,K.A.,et al, 2005
[99mTc]TRODAT-1 SPECT Imaging Correlates with Odor Identification in Early Parkinson Disease
Neurol 64:1716-1720, Siderowf,A.,et al, 2005
Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005
Pallidal vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Arch Neurol 62:554-560,533, Anderson,V.C.,et al, 2005
The Genetic Causes of Basal Ganglia Calcification, Dementia, and Bone Cysts
Neurol 64:1502-1507, Klunemann,H.H.,et al, 2005
Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy
Arch Neurol 62:721-728, Mega,M.S.,et al, 2005
Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease
Arch Neurol 62:753-757, Sparks,D.L.,et al, 2005
Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances
Dept Health & Human Services (Apr), FDA Public Health Advisory, 2005
A-beta Vaccination Effects on Plaque Pathology in the Absence of Encephalitis in Alzheimer Disease
Neurol 64:129-131,10, Masliah,E.,et al, 2005
Migraine and Cerebral White Matter Lesions
The Neurologist 11:19-29, Gladstone,J.P. &Dodick,D.W., 2005
Bone Mineral Density and the Risk of Alzheimer Disease
Arch Neurol 62:107-111, Tan,Z.S.,et al, 2005
A 32-Year Prospective Study of Change in Body Weight and Incident Dementia
Arch Neurol 62:55-60,20, Stewart,R.,et al, 2005
The role of radiotracer imaging in Parkinson disease
Neurol 64:208-215, Ravina, B., et al, 2005
Amorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease
Neurol 64:392-393, Pot, C., et al, 2005
Meningovascular syphilis as a cause of basilar artery stenosis
Neurol 64:391-392, Flint, A.C., et al, 2005
Efficacy of rapid IV administration of valproic acid for status epilepticus
Neurol 64:353-355, Limdi, N.A., et al, 2005
Quantatative Assessment of Driving Performance in Parkinson's Disease
JNNP 76:176-180, 159, Wood, J.M., et al, 2005
Genetic Screening for a Single Common LRRK2 Mutation in Familial Parkinson's Disease
Lancet 365:410-412, Nichols, W.C., et al, 2005
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
Genetic Factors in Alzheimer's Disease
NEJM 352: 862-863, 884, Bird, T., 2005
Unawareness of Cognitive Deficit (Cognitive Anosognosia) in Probable AD and Control Subjects
Neurol 64:693-699, Barrett, A.M., et al, 2005
Steroid Dementia: an Overlooked Diagnosis?
Neurol 64:707-709, Sacks,O. & Shulman,M., 2005
Specialist Palliative Care in Dementia
BMJ 330:57-58, Chen,F. & Majeed,A., 2005
Recent Developments in Pain in Dementia
BMJ 330:461-464, Scherder,E., et al, 2005
Atypical Antipsychotic Drugs and Risk of Ischaemic Stroke: Population Based Retrospective Cohort Study
BMJ 330:445-448, Gill,S.S., et al, 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005